Genomics · Bioinformatics · AI · Translational research
From complex biological data to actionable scientific opportunities. DTS Genomics integrates genomics, advanced bioinformatics, artificial intelligence and translational science to identify, prioritize and develop biologically meaningful hypotheses.
Beyond sequencing
Modern genomics can generate extraordinary amounts of biological information. But sequencing alone does not create therapeutic value.
DTS Genomics operates where data, computation and translational reasoning converge — converting complex datasets into prioritized, testable and scientifically defensible opportunities.
Observation→Hypothesis→Scientific action
From data to biological insight
Positioning
Our platform connects the layers that most organisations keep apart: the data, the computation, the models and the biological judgement that decides what matters.
Molecular profiles, variants, expression patterns and multi-omic information.
Bioinformatics pipelines, biological annotation and advanced analytical models.
Hypothesis generation, pattern recognition and in silico prioritization.
Biological plausibility, validation strategy and development decisions.
Capabilities
Bioinformatics turns heterogeneous biological information into structured, interpretable datasets. AI expands the search space — but algorithms alone are not discovery.
Every computational signal remains subject to biological interpretation and appropriate validation.
Platform workflow
A progressive evidence architecture designed to move from biological observation to decision-ready output.
Genomic, molecular, biological, pharmacological and scientific information is assembled.
Variants, genes, pathways, targets and mechanisms are contextualized.
Bioinformatics and AI identify potentially relevant relationships and hypotheses.
Signals are evaluated according to plausibility, evidence and feasibility.
Promising hypotheses are translated into validation programmes.
Evidence can support R&D decisions, collaboration, licensing or investment evaluation.
Scientific focus
DTS Genomics is designed as a flexible discovery platform capable of addressing multiple areas of biomedical research.
Tumour characterization, target identification, biomarker research and resistance mechanisms.
Rare, neurodegenerative, metabolic and immune-mediated disease mechanisms.
Target discovery, drug repurposing, mechanism analysis and combination hypotheses.
Hypothesis-driven and disease-specific — not technology-led.
Specialized oncology interface
Oncology is one of the most advanced applications of precision genomics. DTS Oncology operates as the specialized oncology-facing component of the broader DTS Genomics ecosystem.
Our difference
Biological discovery requires more than sequencing capacity or computational power. It requires judgement.
Genomic signals are interpreted within pathways, mechanisms and scientific evidence.
AI-generated hypotheses are starting points for investigation — not conclusions.
Opportunities are assessed in the context of validation and therapeutic relevance.
Sources, assumptions, analytical decisions and uncertainty remain identifiable.
Human + computational intelligence
Artificial intelligence can analyse enormous datasets, identify relationships invisible to conventional analysis and explore thousands of hypotheses simultaneously. But biological systems are complex, contextual and frequently non-linear.
AI expands the search space. Scientific reasoning reduces it. Experimental evidence determines what survives.
Evidence & trust
Scientific credibility depends on understanding where a conclusion came from, why it was generated and how strongly it is supported.
Relevant datasets and information sources remain identifiable.
Analytical workflows should be controlled and repeatable.
Prediction, published evidence and validation are clearly separated.
Assumptions, limitations and unresolved questions are explicit.
Expert scientific interpretation remains essential.
Appropriate governance for genomic and biomedical information.
Scientific ambition without compromising scientific discipline.
Collaboration models
We work with biotechnology companies, pharmaceutical developers, research organisations, investors and technology partners seeking genomically informed therapeutic opportunities.
Joint development of hypotheses, targets or biomarkers.
Computational exploration against a defined biological question.
Assay design and experimental confirmation of prioritized signals.
Mechanism-led reassessment of existing compounds.
Independent assessment of assets, targets and evidence.
Shared-risk advancement of a selected programme.
For biotech, pharma & investors
Biopharmaceutical R&D constantly faces the same fundamental problem: there are more scientifically plausible opportunities than resources available to develop them. DTS Genomics helps reduce this decision space by combining genomic evidence, computational analysis and translational reasoning.
Better biological understanding supports better strategic decisions.
Our vision
